GlassScriptPhysician profile
Luis Gonzalez
NPI 1225199698
$1,242.87
in general payments reported to CMS, 2019-2025
18 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $90.16 · 2021: $64.86 · 2022: $178 · 2023: $65.82 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $378.16 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $178.19 | 2019 | |
| Ani Pharmaceuticals, INC. | $173.54 | 2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Novartis Pharmaceuticals Corporation | $95.12 | 2019-2020 | |
| Gilead Sciences, INC. | $69.45 | 2019 | |
| Eyepoint US, INC. | $59.96 | 2022 | |
| Merck Sharp & Dohme LLC | $52.54 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $38.44 | 2023 | |
| Pfizer INC. | $37.66 | 2019-2020 | |
| Harrow Eye, LLC | $33.92 | 2025 | Iheezo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31.01 | 2025 | Rejoyn |
| Boston Scientific Corporation | $23.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.96 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.83 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.57 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.49 | 2020 | |
| Amgen INC. | $12.68 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.